7 recruiting, 5 active not recruiting, 1 completed, 1 not yet recruiting. 11 Phase 1, 4 Phase 2, 1 Phase 3.
By phase and status
Follow Cevostamab: new trials by email Literature Review of Cevostamab trials Research Report on Cevostamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic | Phase 1 | Recruiting | Genentech, Inc. | 46 | 2026-10-31 | 2026-10-06 |
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-10-30 | 2026-10-15 |
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Recruiting | Hoffmann-La Roche | 380 | 2026-06-23 | 2026-10-13 |
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Cevostamab, Tocilizumab - Multiple Myeloma | Phase 1 | Active not recruiting | Hoffmann-La Roche | 20 | 2025-05-13 | 2026-08-28 |
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Cevostamab, Lenalidomide, Tocilizumab - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 200 | 2023-11-14 | 2026-10-06 |
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Cevostamab, Elranatamab, Tocilizumab - Relapsed or Refractory Multiple Myeloma | Phase 1 | Recruiting | Genentech, Inc. | 120 | 2023-08-10 | 2026-10-06 |
Cevostamab Following CAR T Cell Therapy for RRMM
Cevostamab - Relapsed/Refractory Multiple Myeloma | Phase 2 | Active not recruiting | University of Pennsylvania | 30 | 2023-07-11 | 2025-12-18 |
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Cevostamab, XmAb24306, Tocilizumab - Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 90 | 2023-03-21 | 2026-08-11 |
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Cevostamab, Tocilizumab - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 90 | 2022-10-17 | 2026-08-06 |
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Linvoseltamab, Daratumumab, Carfilzomib - Multiple Myeloma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 317 | 2022-08-17 | 2026-07-08 |
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cevostamab, Tocilizumab, Pomalidomide - Multiple Myeloma | Phase 1 | Recruiting | Genentech, Inc. | 186 | 2021-07-26 | 2026-10-20 |
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Cevostamab, Tocilizumab - Multiple Myeloma | Phase 1 | Completed | Genentech, Inc. | 355 | 2017-09-19 | 2026-02-05 |
Conditions studied
Multiple Myeloma (13) · Lupus Erythematosus, Systemic (1) · Neoplasms, Plasma Cell (1) · Recurrence (1)
Sponsors
Genentech, Inc. (6) · Hoffmann-La Roche (5) · Canadian Myeloma Research Group (1) · Regeneron Pharmaceuticals (1) · University of Pennsylvania (1)
Countries
Spain (8) · Australia (7) · France (6) · Israel (6) · United States (6) · South Korea (5) · Canada (4) · Germany (4) · Denmark (3) · Greece (3) · Italy (3) · Poland (3) · China (2) · Czechia (2) · Japan (2)
Top investigators
Adam D Cohen, MD (1) · Suzanne Trudel, MD (1)
Results publications
PMID 42487061
NIH funding
2023 (5), 2025 (2), 2018 (1)